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Inserm, UMR991, Liver Metabolisms and Cancer, F-35033 Rennes, France; Université de Rennes 1, F-35043 Rennes, FranceSummary but also by their microenvironment [1]. The microenvironment isHepatocellular carcinoma (HCC) and intrahepatic cholangiocarci-
noma (ICC) are the most common types of primary tumors in the
liver. Although major advances have been made in understanding
the cellular and molecular mechanisms underlying liver carcino-
genesis, HCC and ICC are still deadly cancers worldwide waiting
for innovative therapeutic options. Growing evidence from the
literature highlight the critical role of the tumor cell microenvi-
ronment in the pathogenesis of cancer diseases. Thus, targeting
the microenvironment, particularly the crosstalk between tumor
cells and stromal cells, has emerged as a promising therapeutic
strategy. This strategy would be particularly relevant for liver
cancers which frequently develop in a setting of chronic inﬂam-
mation and microenvironment remodeling associated with hepa-
tic ﬁbrosis and cirrhosis, such processes in which hepatic stellate
cells (HSC) greatly contribute. This review brings a genomic point
of view on the alterations of the cellular microenvironment in
liver cancers, particularly the stromal tissue within tumor nod-
ules, emphasizing the importance of the crosstalk between tumor
cells and stromal cells, notably activated HSC, in tumor onset and
progression. Furthermore, potential therapeutic modalities of tar-
geting the stroma and HSC are discussed.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
Growing evidence from genetic, genomic, and cell biology indi-
cate that tumorigenesis is determined not only by malignant cells
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vascular endothelial growth factor; IL, interleukin.a complex and dynamic system involving extracellular matrix
(ECM) components, soluble factors, and stromal cells, whose dis-
tribution and composition vary in space and time [1–3]. Under
physiological condition, the microenvironment serves as an
important barrier to epithelial cell transformation, notably by
maintaining cell polarity and by controlling cell proliferation
[1–3]. In response to emerging epithelial cancerous lesions, the
microenvironment experiences important changes (e.g., recruit-
ment/activation of stromal cells, ECM remodeling) which contrib-
ute to cancer initiation and progression and inﬂuence the
therapeutic response [1–3]. Thus, targeting the tumor microenvi-
ronment is now viewed as a promising strategy to treat cancer in
a variety of organs including liver [3,4]. Hepatocellular carcinoma
(HCC) and intrahepatic cholangiocarcinoma (ICC) are the two
major types of primary tumors in the liver. Alteration of the
microenvironment is a hallmark of liver carcinogenesis given that
more than 80% of tumors arise in a setting of chronic inﬂamma-
tion associated with liver ﬁbrosis and/or cirrhosis, conditions
which constitute real precancerous stages [4]. As key drivers of
liver ﬁbrosis and ECM remodeling [5], activated hepatic stellate
cells (HSC) might represent attractive targets in the design of
innovative therapeutic strategies against the stroma in liver car-
cinogenesis.
Key Points
• Liver carcinogenesis represents a paradigm to study 
the role of the microenvironment in cancer given that 
most tumors develop in a background of liver fibrosis/
cirrhosis
• Tumor cell microenvironment remodeling is associated 
with tumor progression
• HSC play an important role in liver carcinogenesis 
as key modulators of fibrosis and tumor cell 
microenvironment
• Targeting HSC and the crosstalk between tumor and 
stromal cells may represent a promising therapeutic 
strategy14 vol. 60 j 1306–1309
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The tumor microenvironment in liver carcinogenesisThe tumor microenvironment includes cellular and non-cellular
components. In the liver, HSC, ﬁbroblasts, myoﬁbroblasts as well
as immune and endothelial cells represent the main cell types of
the hepatocyte microenvironment [4]. In addition to ECM macro-
molecules (e.g., collagens, proteoglycans), non-cellular compo-
nents include diverse soluble factors such as cytokines and
growth factors that can be stored into the ECM and orchestrate
the interplay between tumor cells and the microenvironment
[1–4].
A combination of cell and molecular biology, biochemistry,
histopathology and gene to gene approaches greatly contributed
to identify pathways deregulated in the tumor stroma and their
impact on tumor cells [1]. Recently, genomic approaches revis-
ited the ﬁeld allowing an exhaustive and integrated view of these
deregulations at a pangenomic scale [6]. Even more, by combin-
ing laser microdissection and gene expression proﬁling, stromal
gene signatures linked to clinical outcomes were established in
cancer [6]. This approach was proven to be fruitful for decipher-
ing the molecular mechanisms underlying the alterations of the
tumor microenvironment, with the ultimate goal of designing
new therapeutic approaches, and identifying novel diagnostic
and prognostic biomarkers [6]. In liver, few studies addressed this
issue at a genomic scale. In HCC, gene expression proﬁling high-
lighted the importance of Th1 and Th2 cytokines in the surround-
ing non-tumor tissue of HCC associated with metastasis [7]. A
metastasis-inclined microenvironment signature was character-
ized by an increase in Th2 cytokines and a decrease in Th1 cyto-
kines [7]. This study suggested that the dynamics of the immune
microenvironment in the non-tumor tissue adjacent to the tumor
nodules may result in the establishment of a suitable niche to
promote tumor cell dissemination. Genomic studies also pro-
vided molecular insight into the pathogenesis of ICC, which is
usually characterized by a dense desmoplastic stroma [8]. From
these studies clinically relevant ICC subgroups were highlighted
and new therapeutic opportunities were proposed, based on
BRAF/KRAS mutations and activation of oncogenic pathways
(e.g., receptor tyrosine kinases) [8]. Recently, we identiﬁed spe-
ciﬁc alterations of the stroma in ICC through an unsupervised
analysis of microdissected human tumors [9]. Thus, a signature
which included genes related to cell cycle, ECM, and transforming
growth factor beta (TGFb) pathways was shown to signiﬁcantly
discriminate the tumor stroma from ﬁbrous tissue isolated in
the adjacent non tumor liver. A clear correlation between geno-
mic changes in the stroma and the aggressiveness of ICC was also
demonstrated. Notably, high stromal expression of osteopontin
and TGFb was identiﬁed as poor prognosis factor [9]. Besides
promising biomarkers, osteopontin and TGFb represent potential
therapeutic targets, given their proven role in driving the onco-
genic process from early stages of tumor development to late
invasive stages. Indeed, gain and loss of function studies demon-
strated osteopontin to be crucial for tumor cell growth and
metastasis, notably by mechanisms involving apoptosis escape,
angiogenesis, and ECM degradation [10]. Activation of the TGFb
signaling was found in HCC [11], ICC [9], and combined HCC-
ICC [12]. Importantly, studies using engineered mice demon-
strated that the modulation of the TGFb pathway in stromal
ﬁbroblasts inﬂuences the oncogenic potential of the adjacent epi-
thelial cells [2]. These results imply that genomic alterations in
stromal cells may result in tumor initiation and progression.Journal of Hepatology 2014HSC in tumor onset and progression
The activation of HSC and subsequent phenotypic changes
towards a myoﬁbroblast-like phenotype is a key event in liver
ﬁbrosis [5]. Gene expression studies showed that activated HSC
markedly express genes involved in ﬁbrogenesis and ﬁbrolysis,
inﬂammation and apoptosis [13]. HSC activation is controlled
by numerous factors and signaling pathways (e.g., TGFb, plate-
let-derived growth factors (PDGF), hedgehog, notch, microRNAs)
[5]. Recently, the hedgehog signaling was shown to control the
fate of HSC, thus opening new opportunities for a therapeutic tar-
geting of HSC [14]. The nuclear factor-kappa B (NF-jB) pathway
has been also reported to contribute to HSC activation and sur-
vival, and more largely to be a central factor in the progression
of hepatic diseases, linking liver injury, inﬂammation, ﬁbrosis,
and HCC (reviewed in [15]).
Besides a major role in ﬁbrogenesis, HSC exhibit biological
functions that inﬂuence the onset and the progression of HCC
[5]. Thus, HSC can induce phenotypic changes in cancer cells,
notably through the production of growth factors and cytokines
in favor of tumor cell proliferation (e.g., hepatocyte growth factor,
interleukin-6 (IL-6)) [5,16]. Migration and proliferation of HCC
cells are also modulated by ECM components produced by acti-
vated HSC, including basement membrane components, e.g., lam-
inin-5 [17]. Interestingly, HSC were reported as key players in
liver tumorigenesis associated with the gut-liver axis [18]. Thus,
the gut microbiome was shown to induce inﬂammatory and ﬁbr-
ogenic responses, and HSC activation leading to the production of
epiregulin, a mitogenic factor for hepatocytes [18]. Cellular and
molecular approaches demonstrated that a bidirectional crosstalk
exists between HSC-derived myoﬁbroblasts and tumor hepato-
cytes [5]. Early studies showed that the exposition of HSC to con-
ditioned media derived from HCC tumor cells resulted in HSC
activation, migration and expression of pro-angiogenic factors
such as vascular endothelial growth factor alpha (VEGFA) [5].
Recently, we reported that the crosstalk between hepatoma cells
and activated HSC also increased the expression of proinﬂamma-
tory cytokines and chemokines (e.g., IL-6, IL-8), and modiﬁed the
phenotype of hepatoma cells toward motile cells, together with
the generation of a permissive pro-angiogenic microenviron-
ment, characterized by the overexpression of VEGFA and matrix
metallopeptidase 9 (MMP9) in HSC [19]. Interestingly, integrative
genomics demonstrated that a gene signature of this crosstalk
was predictive of a poor prognosis and metastasis propensity in
human HCC [19]. In addition to pro-inﬂammatory cytokines,
TGFb was reported to be central in driving the pro-tumorigenic
effects of activated HSC on the progression of transformed hepa-
tocytes [20]. Interplay between HSC and cancer cells has also
been reported in ICC, notably through the SDF1/CXCR4 axis
whose activation was shown to inﬂuence both cancer cell sur-
vival and metastasis [21]. In addition to early stages of tumor
development, HSC are involved in late tumor stages, notably by
producing factors that directly participate in the formation of a
pro-metastatic microenvironment [16]. Such factors in favor of
the metastatic growth of tumor cells include inducers of the epi-
thelial to mesenchymal cell transition (EMT), modulators of ECM
synthesis and degradation, pro-angiogenic and immune-suppres-
sion factors (e.g., TGFb, ECM proteins, MMP, VEGFA) [16]. HSC can
produce immune-regulatory cytokines (e.g., MCP1, RANTES,
CCL21) to promote chemotaxis, adherence, and activation of
inﬂammatory cells [5,22]. Paracrine interactions of HSC withvol. 60 j 1306–1309 1307
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HSC
Clinical Application of Basic Science
endothelial cells have been reported, as well as the secretion of
VEGFA and angiopoietins by HSC favoring a pro-angiogenic
microenvironment [22].Tumor
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Fig. 1. Therapeutic potential of targeting HSC and the stroma in liver cancer.
Depicted is the interplay between tumors cells and components of the micro-
environment, notably HSC, which inﬂuence tumor progression by creating a
permissive environment and by perverting the phenotype of tumor cells. Each of
these interactions, symbolized by arrows, could be targeted for therapeutic
purpose. Epigenetic modulation of the crosstalk between tumor cells and their
microenvironment may also open new therapeutic opportunities in liver cancers.Therapeutic targeting of tumor microenvironment and HSC
Targeting the microenvironment is emerging as a promising
strategy given the well-recognized role of the stroma in carcino-
genesis [3]. Examples of drugs targeting the microenvironment
include anti-angiogenic and anti-proliferative agents such as bev-
acizumab, an inhibitor of VEGFA, cetuximab, an inhibitor of EGFR,
and sorafenib, an inhibitor of multiple protein kinase receptors
(e.g., EGFR, VEGFR, PDGFR) [4]. Interestingly, sorafenib, which is
currently the only drug recommended for advanced HCC, was
shown to reduce the proliferation of transformed hepatocytes
but also to attenuate liver ﬁbrosis, notably by reducing HSC pro-
liferation and ECM accumulation [23]. This observation opens an
opportunity to target not only the tumor cells but also their
microenvironment. One can expect that a better understanding
of the cellular and molecular mechanisms underlying the process
of HSC activation/proliferation, and ECM remodeling associated
with tumor onset and progression may open opportunities to
design new lines of therapeutic approaches. Therapeutic target-
ing of HSC has been investigated with interest given the key role
of HSC in ﬁbrosis and HCC [22]. Induction of cellular apoptosis or
senescence and reversion of activated HSC toward a quiescent
state have been proposed as mechanisms to clear activated HSC
[22]. For example, selective induction of HSC apoptosis may be
achieved by nanoparticles or gene transfer systems designed to
inhibit the transcription factor NF-jB which controls HSC activa-
tion and proliferation [15]. Boosting speciﬁc immune cell popula-
tions may represent another innovative strategy to control HSC.
Recently, hepatic cd T cells have been shown to promote the
apoptosis of HSC through a mechanism involving the Fas-ligand
[24]. NK cells have been also shown to selectively kill early or
senescent activated HSC and to produce anti-ﬁbrotic cytokines
such as IFNc [22]. Among immune effectors which exhibit anti-
ﬁbrotic potentials (e.g., IFNc, IL-22, IL-10), IL-22 was reported
as a potent inducer of HSC senescence [22].
Targeting the crosstalk between tumors cells and their micro-
environment may also represent a promising therapeutic strat-
egy. Exploring this possibility, we recently applied an
integrative functional genomics approach to identify molecules
that could interfere with the crosstalk between hepatocytes and
HSC [19]. Thus, by using a connectivity map algorithm we were
able to connect a gene signature of the hepatocyte-HSC crosstalk
with trichostatin A, an inhibitor of histone deacetylases. Accord-
ingly, the effects of the crosstalk on tumor cell migration and
endothelial cell angiogenesis were reversed in presence of tri-
chostatin A, suggesting that epigenetic modulators may be clini-
cally relevant [19]. Soluble factors may be also targeted to
modulate the communication between the tumor cells and the
microenvironment. In that regard, TGFb may represent a promis-
ing target given that this cytokine is involved in multiple stages
of liver carcinogenesis. TGFb exhibits both oncogenic and tumor
suppressive properties depending on tumor stage [11,25]. As
mentioned above, at preneoplastic stages TGFb acts as a potent
inducer of HSC activation and ﬁbrogenesis but also exhibits
growth-inhibitory and apoptosis-inducing effects, and in
advanced stages TGFb promotes HCC/ICC tumor cell invasion,
notably as an inducer of EMT [11,25]. Thus, therapeutic targeting1308 Journal of Hepatology 2014of the TGFb pathway should be appropriately designed to inhibit
its oncogenic properties while retaining its cytostatic effects. Tar-
geting TGFb signaling by using small molecule inhibitors (e.g.,
LY2109761) or neutralizing antibodies has shown promising
results in experimental HCC mouse models, including inhibition
of cell invasion and abrogation of neo-angiogenesis [25]. Inhibi-
tion of the TGFb signaling was also reported to be effective in
blocking tumor-stroma crosstalk and tumor progression in HCC
[25]. Thus, appropriately interfering with the crosstalk between
cancer cells and their microenvironment may open new thera-
peutic opportunities in liver cancers (Fig. 1).Conclusive remark
Advances in understanding the molecular mechanisms involved
in the crosstalk between tumor cells and their microenvironment
at the pangenomic scale open the path to design new lines of
therapeutic approach and associated biomarkers. Recent ﬁndings
highlight that future adapted therapeutics would target both the
tumor cells and the microenvironment by favorably modulating
speciﬁc regulators in cellular pathways, and widespread mecha-
nisms related to the neoplastic stroma evolution.Financial support
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